Protara Therapeutics, Inc. (NASDAQ:TARA) Short Interest Update

Protara Therapeutics, Inc. (NASDAQ:TARA) saw a large decrease in short interest in January. As of January 15th, there was short interest totalling 4,400,000 shares, a decrease of 13.7% from the December 31st total of 5,100,000 shares. Based on an average daily volume of 2,270,000 shares, the short-interest ratio is presently 1.9 days.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. Guggenheim restated a “buy” rating and issued a $20.00 price target on shares of Protara Therapeutics in a research note on Friday, December 6th. HC Wainwright restated a “buy” rating and issued a $23.00 target price on shares of Protara Therapeutics in a research report on Friday, December 6th.

Institutional Investors Weigh In On Protara Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC boosted its stake in shares of Protara Therapeutics by 21.0% in the 3rd quarter. Geode Capital Management LLC now owns 170,040 shares of the company’s stock worth $311,000 after buying an additional 29,514 shares during the last quarter. XTX Topco Ltd bought a new position in shares of Protara Therapeutics in the third quarter worth $60,000. Oppenheimer & Co. Inc. increased its holdings in shares of Protara Therapeutics by 40.8% in the third quarter. Oppenheimer & Co. Inc. now owns 179,125 shares of the company’s stock worth $328,000 after purchasing an additional 51,944 shares during the period. Renaissance Technologies LLC increased its holdings in shares of Protara Therapeutics by 77.8% in the second quarter. Renaissance Technologies LLC now owns 150,400 shares of the company’s stock worth $313,000 after purchasing an additional 65,800 shares during the period. Finally, Marshall Wace LLP purchased a new position in Protara Therapeutics in the second quarter worth $161,000. 38.13% of the stock is owned by institutional investors.

Protara Therapeutics Stock Performance

NASDAQ:TARA opened at $4.92 on Monday. The firm has a market cap of $101.50 million, a P/E ratio of -1.74 and a beta of 1.64. Protara Therapeutics has a 52 week low of $1.60 and a 52 week high of $10.48. The firm’s fifty day moving average is $4.95 and its 200-day moving average is $3.09.

Protara Therapeutics (NASDAQ:TARA) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.50) earnings per share for the quarter, hitting the consensus estimate of ($0.50). As a group, sell-side analysts anticipate that Protara Therapeutics will post -3.32 earnings per share for the current year.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.